ChristianaCare Gene Editing Institute

We don’t know the future of this platform for news & knowledge sharing. Just in case, here’s where else you can connect with us: Facebook: facebook.com/GeneEditingDE/ Instagram: instagram.com/geneeditingde/ LinkedIn: linkedin.com/company/christ… #TwitterDown #TwitterShutdown

Our research shows we can use gene editing to make lung cancer tumors more sensitive to chemo. Learn more about our breakthrough research and how it could one day help people fight #lungcancer: insideprecisionmedicine.com/topics/oncolog…

We've been featured in our parent organization's 2024 annual report, highlighting the importance of gene editing research to the continued advancement of disease treatment. Read more here: christianacare.org/us/en/about-us…

We're thrilled to be among the Top 16 in the "Coolest Thing Made in Delaware" contest! Huge thanks to everyone who voted so far! Head to dscc.com/mfg and cast your vote for CRISPR in a Box! #CoolestThingDE

Although a federal judge has blocked the Trump administration’s cap on critical funding for medical and scientific research, higher education officials in Delaware are still concerned it could have serious ramifications on innovation in the First State. delawarebusinesstimes.com/insider-only/l…

How do we shape the future? One student at a time. Listen to the newest episode of 'For the Love of Health' to hear how we bring students into an immersive CRISPR experience! youtube.com/watch?v=xBVNt4…

CorriXR named one of 4 companies to watch in the accelerating #geneediting race by @Clarivate @PharmaVoice #CRISPR #Oncology #biotech pharmavoice.com/news/biotech-w…

We're proud to see London McGill, one of our staff scientists, recognized for her presentation at the @AACR. McGill presented research on an approach for using CRISPR as a therapy for the treatment of pancreatic cancer. udel.edu/udaily/2024/oc…

It's tomorrow! Join us at Advanced Therapies in Philadelphia to get an insightful glimpse of the field as a whole - from CarT to cell barriers to CRISPR therapeutics! We're presenting and exhibiting, and we hope to see you there! terrapinn.com/congress/advan…

As a nonprofit organization, we rely on philanthropy and donations to continue bringing genomic science to the forefront of medical research while we inspire the next generation of scientists. Interested in supporting us? Visit giving.christianacare.org/gene-editing-i… . Every dollar helps!

Nothing's scary about CRISPR, but there's something spooky about our scientists today! We're enjoying the holiday by dressing up. To all the trick-or-treaters and celebrators of the day: go 'bananas' tonight, but don't go too crazy on the candy - maybe just a 'bite'!

Make sure you don't miss this opportunity to learn about our current research efforts! We hope to see you there!

RT @CorriXR: CorriXR announces the appointment of @JillCastilla to our Board of Directors. She brings visionary leadership as a nationally…

.@DelawareBio elected two new members to its board of directors: Natalia Rivera-Torres of @GeneEditingDE and Bruce Sachais of the Blood Bank of Delmarva and New York Blood Center Enterprises. delawarebio.org/news/677611/

Our scientific director Eric Kmiec is speaking at Advanced Therapies USA 2024 between November 12-13! Be sure to join his session at America’s leading cell and gene event. Click below now to sign up as his guest! #ADTherapiesUSA i.snoball.it/p/fIW4/sm/1

𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐍𝐞𝐰 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐭𝐨 𝐄𝐧𝐡𝐚𝐧𝐜𝐞 𝐂𝐑𝐈𝐒𝐏𝐑–𝐂𝐚𝐬9-𝐌𝐞𝐝𝐢𝐚𝐭𝐞𝐝 𝐇𝐨𝐦𝐨𝐥𝐨𝐠𝐨𝐮𝐬 𝐑𝐞𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 In a hunt for ways to improve the efficiency of CRISPR–Cas9-mediated homologous recombination, researchers at ETH Zürich and Memorial Sloan Kettering Cancer Center find that a single exonuclease, TREX1, reduces HDR efficiency when the repair template is a single-stranded or linearised double-stranded DNA. TREX1 knockout improved HDR efficiency, indicating new avenues for increasing CRISPR-Cas9-mediated HDR in TREX1-expressing contexts. The study was led by Jacob Corn at ETH Zürich. crisprmedicinenews.com/news/researche… #crisprmedicinenews #crisprmedicine #crisprcas9 #fanconianemia #geneediting

Using CRISPR-Cas9 to knock out CD5, researchers have significantly improved the efficacy of adoptive T-cell therapies for both haematological and solid cancers. We're proud to highlight our fellow researchers in the mid-Atlantic region. crisprmedicinenews.com/news/crispr-en…

In this study, the first example of heritable gene editing in the entire phylum of Tardigrada was researched, evaluated, and deemed a success. This foray into the world of 'water bears' could have major implications for human genome editing in the future. journals.plos.org/plosgenetics/a…

Human cells repair RNA breaks induced by a programmable CRISPR system, paving the way for temporary treatments for genetic diseases. the-scientist.com/a-crispr-tool-…

A team of scientists at Gladstone Institutes has developed a new method that enables them to make precise edits in multiple locations within a cell all at once, opening up the ability to map treatments for complex genetic diseases. gladstone.org/news/new-one-s…

A recent British study at the University of Bristol indicates that the last universal common ancestor (LUCA) possessed an early form of the CRISPR-Cas immune system, dating back approximately 4.2 billion years. crisprmedicinenews.com/news/crispr-or…